Sequella Is A Privateclinical Stage Pharmaceutical Company That Addresses The Challenge Of Antibiotic Resistant Bacterial Diseases By Discoverydevelopmentand Commercialization Of First In Class Antibiotics With Novel Mechanisms Of Actionour Lead Drug Candidate Identified From Our Current150 000 Proprietary Compound Librarysq109Is In Phase 2 Clinical Trials For Treatment Of Both Tuberculosistband Gastritishelicobacter Pylori Infections Diseases Complicated By Growing Resistance To Existing Drugsin 2013We Acquired A New Clinical Stagephase 2Oxazolidinonesutezolidfor Treatment Of Tb And Other Resistant Bacterial Diseaseswe Also Have A Vigorous Research Program To Develop Novel Antibiotics That Target The Enzyme Translocase 1An Essential Enzyme In All Bacteria Our Product Portfolio Addresses Global Health Threats With Significant Market Opportunity In Disease Areas Of Known Or Suspected Infectious Etiology Tbmycobacterium Tuberculosis Duodenal Ulcershelicobacter Pylori Gastric Carcinomashelicobacter Pylori Cdiclostridium Difficile Crohn S Diseasemycobacterium Avium Paratuberculosis Chagas Diseasetrypanosoma Cruzi
